AMACR and dysplasia: The negative rates of AMACR expression in overall lesions were 15.1 ± 23.9%, 49.0 ± 29.9%, and 59.0 ± 32.2% in low- and high-grade dysplasia and gastric adenocarcinoma groups, respectively (Figure 2).